Juno Therapeutics (JUNO) Shareholder Baillie Gifford & Company Lowered Its Stake as Market Value Rose; Microsoft (MSFT) Shareholder Verity & Verity Lowered Its Stake

February 17, 2018 - By Marguerite Chambers

Baillie Gifford & Company decreased its stake in Juno Therapeutics Inc (JUNO) by 2.91% based on its latest 2017Q3 regulatory filing with the SEC. Baillie Gifford & Company sold 324,729 shares as the company’s stock rose 2.20% with the market. The institutional investor held 10.85 million shares of the health care company at the end of 2017Q3, valued at $486.66M, down from 11.17 million at the end of the previous reported quarter. Baillie Gifford & Company who had been investing in Juno Therapeutics Inc for a number of months, seems to be less bullish one the $9.82 billion market cap company. The stock decreased 0.41% or $0.35 during the last trading session, reaching $85.1. About 3.05M shares traded. Juno Therapeutics, Inc. (NASDAQ:JUNO) has declined 39.85% since February 17, 2017 and is downtrending. It has underperformed by 56.55% the S&P500.

Verity & Verity Llc decreased its stake in Microsoft Corp (MSFT) by 4.56% based on its latest 2017Q3 regulatory filing with the SEC. Verity & Verity Llc sold 6,015 shares as the company’s stock rose 4.75% with the market. The institutional investor held 125,769 shares of the prepackaged software company at the end of 2017Q3, valued at $9.37 million, down from 131,784 at the end of the previous reported quarter. Verity & Verity Llc who had been investing in Microsoft Corp for a number of months, seems to be less bullish one the $708.38 billion market cap company. The stock decreased 0.71% or $0.66 during the last trading session, reaching $92. About 30.60 million shares traded or 7.87% up from the average. Microsoft Corporation (NASDAQ:MSFT) has risen 34.52% since February 17, 2017 and is uptrending. It has outperformed by 17.82% the S&P500.

Investors sentiment increased to 0.83 in 2017 Q3. Its up 0.01, from 0.82 in 2017Q2. It increased, as 40 investors sold MSFT shares while 952 reduced holdings. 114 funds opened positions while 708 raised stakes. 5.51 billion shares or 0.32% less from 5.53 billion shares in 2017Q2 were reported. Pine River Cap Lp holds 4,997 shares. Swedbank stated it has 11.50M shares or 5.24% of all its holdings. Balasa Dinverno & Foltz Limited Liability Company reported 0.55% of its portfolio in Microsoft Corporation (NASDAQ:MSFT). 80,792 were accumulated by Bkd Wealth Advisors Ltd. Mitchell Sinkler And Starr Pa invested in 6,410 shares. Excalibur Corporation accumulated 53,847 shares. Pennsylvania stated it has 457,988 shares. Com Of Toledo Na Oh invested in 2.58% or 136,170 shares. Bnp Paribas Asset Sa reported 2.63 million shares. Neville Rodie Shaw Incorporated stated it has 1.54% in Microsoft Corporation (NASDAQ:MSFT). Loeb Prtn reported 1.45% stake. Btr Cap Management invested 3.49% in Microsoft Corporation (NASDAQ:MSFT). Lehman Fin Res Inc has 0.12% invested in Microsoft Corporation (NASDAQ:MSFT). Fjarde Ap has 2.43% invested in Microsoft Corporation (NASDAQ:MSFT). Moreover, Nbw Cap Ltd has 2.4% invested in Microsoft Corporation (NASDAQ:MSFT).

Verity & Verity Llc, which manages about $217.83M and $342.96 million US Long portfolio, upped its stake in Aflac Inc (NYSE:AFL) by 5,285 shares to 36,140 shares, valued at $2.94M in 2017Q3, according to the filing. It also increased its holding in Amgen Inc (NASDAQ:AMGN) by 2,414 shares in the quarter, for a total of 14,609 shares, and has risen its stake in Alps Etf Tr (AMLP).

Among 37 analysts covering Microsoft Corporation (NASDAQ:MSFT), 29 have Buy rating, 2 Sell and 6 Hold. Therefore 78% are positive. Microsoft Corporation had 167 analyst reports since July 22, 2015 according to SRatingsIntel. Vetr upgraded Microsoft Corporation (NASDAQ:MSFT) rating on Wednesday, September 2. Vetr has “Strong-Buy” rating and $47.60 target. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, January 23. Credit Suisse maintained Microsoft Corporation (NASDAQ:MSFT) on Wednesday, January 31 with “Buy” rating. Deutsche Bank maintained the stock with “Buy” rating in Wednesday, December 16 report. The stock of Microsoft Corporation (NASDAQ:MSFT) earned “Buy” rating by Nomura on Friday, February 2. The firm earned “Buy” rating on Thursday, January 25 by Canaccord Genuity. Bernstein maintained it with “Buy” rating and $100.0 target in Tuesday, December 12 report. The rating was maintained by UBS with “Buy” on Friday, July 21. Stifel Nicolaus maintained Microsoft Corporation (NASDAQ:MSFT) rating on Monday, July 3. Stifel Nicolaus has “Buy” rating and $7300 target. Cowen & Co maintained the stock with “Buy” rating in Friday, July 21 report.

Since August 29, 2017, it had 0 insider purchases, and 2 selling transactions for $5.98 million activity. On Wednesday, August 30 COURTOIS JEAN PHILIPPE sold $1.98M worth of Microsoft Corporation (NASDAQ:MSFT) or 26,763 shares.

Analysts await Juno Therapeutics, Inc. (NASDAQ:JUNO) to report earnings on March, 7. They expect $-1.02 EPS, down 54.55% or $0.36 from last year’s $-0.66 per share. After $-1.12 actual EPS reported by Juno Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -8.93% EPS growth.

Among 19 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 2 have Buy rating, 0 Sell and 17 Hold. Therefore 11% are positive. Juno Therapeutics Inc had 57 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Tuesday, January 23 by Maxim Group. Suntrust Robinson downgraded it to “Hold” rating and $25 target in Friday, November 25 report. The stock of Juno Therapeutics, Inc. (NASDAQ:JUNO) earned “Sell” rating by BTIG Research on Thursday, June 8. The firm earned “Buy” rating on Monday, August 24 by Standpoint Research. The firm earned “Hold” rating on Friday, November 25 by SunTrust. The company was downgraded on Tuesday, December 6 by Raymond James. On Wednesday, November 23 the stock rating was maintained by Maxim Group with “Buy”. The stock has “Buy” rating by SunTrust on Thursday, November 2. Wells Fargo maintained Juno Therapeutics, Inc. (NASDAQ:JUNO) rating on Wednesday, January 17. Wells Fargo has “Hold” rating and $63.0 target. The rating was maintained by Morgan Stanley on Monday, August 7 with “Equal-Weight”.

Investors sentiment increased to 1.44 in Q3 2017. Its up 0.11, from 1.33 in 2017Q2. It is positive, as 26 investors sold JUNO shares while 46 reduced holdings. 51 funds opened positions while 53 raised stakes. 66.13 million shares or 23.59% more from 53.50 million shares in 2017Q2 were reported. 61,877 were accumulated by Creative Planning. Moreover, Bb Biotech Ag has 2.55% invested in Juno Therapeutics, Inc. (NASDAQ:JUNO) for 2.06 million shares. Pinnacle Limited holds 6,130 shares or 0.01% of its portfolio. Moreover, Baillie Gifford has 0.62% invested in Juno Therapeutics, Inc. (NASDAQ:JUNO) for 10.85 million shares. 11,365 were accumulated by Raymond James Finance Svcs Advisors. Federated Invsts Incorporated Pa holds 23,434 shares or 0% of its portfolio. Sib Ltd Llc reported 3.22% in Juno Therapeutics, Inc. (NASDAQ:JUNO). 22,000 were accumulated by Fred Alger Inc. 57,727 were reported by Ubs Asset Americas. Nuveen Asset Mgmt Ltd Liability Corporation stated it has 15,477 shares or 0% of all its holdings. Motco owns 0% invested in Juno Therapeutics, Inc. (NASDAQ:JUNO) for 40 shares. Rockefeller Financial Services invested 0% in Juno Therapeutics, Inc. (NASDAQ:JUNO). Mitsubishi Ufj Tru Bk Corporation owns 898,040 shares for 0.07% of their portfolio. Arrowmark Colorado Holdg Lc has invested 0.67% in Juno Therapeutics, Inc. (NASDAQ:JUNO). Montana-based Da Davidson And has invested 0.19% in Juno Therapeutics, Inc. (NASDAQ:JUNO).

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>